Published: 2021-02-24

Immunohistochemical expression of P53 and Ki-67 on epithelial tumors of ovary

Ipsita Mohapatra, Nikku Harshini, Subha Ranjan Samantaray, K. Anantha Sahitya


Background: Ovarian cancer is the third most common gynaecologic cancer and it is well known for its late presentation at advanced stage. Epithelial tumors of the ovary (EOT) are commonest of all ovarian neoplasms and their malignant forms represent about 90% of ovarian cancers. The determination of cell proliferation has been reported to be of diagnostic and prognostic significance. Over expression of p53 and Ki-67 has been claimed to be a marker of poor prognosis in epithelial ovarian tumors. Aim this study was to evaluate the biological significance of p53 and Ki-67 and their antigen expression in epithelial ovarian cancer.

Methods: This is an observational study of 52 cases of ovarian tumors which were diagnosed and operated at Dept of Gynaecology, Prathima institute of medical sciences in South India, between August 2018 to July 2020.

Results: The mean age of diagnosis for benign, borderline and malignant epithelial tumors was 42years, 49 years, 56years respectively. Most common histological type was serous epithelial tumors (50%). Highest p53 and Ki-67 immunoreactivity was seen in malignant tumors. Their co-expression was seen in 46.2% of the cases.

Conclusions: Epithelial tumors and their malignant forms are common ovarian cancers, which are well known for its lethality and late presentation. Immunohistochemical markers p53 and Ki-67 frequently over expressed in epithelial tumors and has a prognostic role in determining the biologic tumor behaviour which further helps in planning the treatment.


Epithelial ovarian tumor, Immumohistochemistry, Ki-67, p53

Full Text:



Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

Berek JS, English DP, longacre TA, Friedlander M. Ovarian, Fallopian Tube and Peritoneal Cancer.In: Berek JS, Berek DL. Berek& Novak’s Gynecology. 16th ed. Philadelphia: Wolters Kluwer; 2019. P.1077-1142.

Mahadevappa A, Krishna SM, Vimala MG. Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma. J Clin Diagn Res. 2017;11(2):EC08-EC12.

Qasim YA, Saeed SZ, Rashid IM. Immunohistochemical Study of P53 and Ki 67 Expression in Surface Epithelial Tumor of the Ovary. Saudi J. Pathol. Microbiol. 2017;2(3):52-9.

Li LT, Jiang G., Chen Q, Zheng JN."Ki-67 is a promising molecular target in the diagnosis of cancer (Review)". Molecular Medicine Reports 11.3. 2015: 1566-72.

Risques RA, Kennedy SR. Aging and the rise of somatic cancer-associated mutations in normal tissues. PLoS Genet. 2018;14(1):e1007108.

Luminita NG, Carmen U, Maria SM. The immunohistochemical expression of P53 and ki-67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Rom J Morphol Embryol. 2012;53(4):967-73.

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287-99.

Laishram S, Gupta V, Bhake A, Wankhede A, Agrawal D. To assess the utility of proliferative marker Ki-67 in surface epithelial ovarian tumor. J Datta Meghe Inst Med Sci Univ. 2019;14:6-10.

Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989;57(7):1083-93.

Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351(6326):453-6.

de Graeff P, Crijns AP, de Jong S, et al. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer. 2009;101(1):149-59.

Romus, I, Triningsih FX, Mangunsudirdjo S, Harijadi A. Clinicopathology Significance of p53 and p63 Expression in Indonesian Cervical Squamous Cell Carcinomas. Asian Pac J Cancer Prev. 2013;14(12):7737-41.

Levesque MA, Katsaros D, Zola P, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer. 1995;75:1327-38.

Sylvia MT, Kumar S, Dasari P.The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2- neu, p53 and ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol. 2012;55(1):33-7.

Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer. 2003;97(2):389-404.

Skirnisdottir I, Sorbe B, Seidal T. P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. Int J Gynecol Cancer. 2001;11:147-58.

Milner BJ, Allan LA, Eccles DM, et al. P53 mutations is a common genetic event in ovarian carcinoma. Cancer Res. 1993;53:2128-32.

Gottlieb WH, Berek JS. Advances in the biology of gynecologic cancer. CurrOpin Oncol. 1994;6:513-8.

Hall PA, Levison DA. Review: assessment of cell proliferation in histological material. J Clin Pathol. 1990;43:184-92.

Gursan N, Sipal S, Calik M, Gundogdu C. P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms. Eurasian J Med. 2009;41(1):10-4.

Kamal CK, Simionescu CE, Mărgăritescu C, Stepan A. P53 and Ki-67 immunoexpression in mucinous malignant ovarian tumors. Rom J Morphol Embryol. 2012;53(3):799-803.

Khouja MH, Baekelandt M, Nesland JM, Holm R. The clinical importance of ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol. 2007;26:418-25.